Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year

Generics Launches In 2022 Will ‘Affect The Second Half’ Of The Year

 
• By Dean Rudge
  
business growth
Teva has seen its margins climb since a low in 2019 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business